Unlock stock picks and a broker-level newsfeed that powers Wall Street.

OTC Markets OTCPK - Delayed Quote USD

DBV TECHNOLOGIES (DBVTF)

0.7859
0.0000
(0.00%)
At close: May 2 at 4:00:00 PM EDT
All All Favorites Text Statistics Technicals Fibonacci Markings Lines
Loading Chart for DBVTF

Recent News: DBVTF

View More
DBV Technologies Reports First Quarter 2025 Financial Results

DBV Technologies Reports First Quarter 2025 Financial Results
GlobeNewswire 2 days ago
Why DBV Technologies S.A. (DBVT) is Surging in 2025

Why DBV Technologies S.A. (DBVT) is Surging in 2025
Insider Monkey 2 days ago
DBV Technologies announces filing of 2024 Annual Report on Form 10-K and Universal Registration Document

DBV Technologies announces filing of 2024 Annual Report on Form 10-K and Universal Registration Document
GlobeNewswire 21 days ago
Novo gains Lexicon obesity drug; CRISPR COO to step down

Novo gains Lexicon obesity drug; CRISPR COO to step down
BioPharma Dive last month
DBV Technologies Announces Financing of up to $306.9 Million (€284.5 Million) to Advance Viaskin® Peanut Patch Through Biologics License Application Submission and U.S. Commercial Launch, if Approved

DBV Technologies Announces Financing of up to $306.9 Million (€284.5 Million) to Advance Viaskin® Peanut Patch Through Biologics License Application Submission and U.S. Commercial Launch, if Approved
GlobeNewswire last month
DBV Technologies Secures Agreement with FDA on Safety Exposure Data Required for BLA for Viaskin® Peanut Patch in 4–7-year-olds, Accelerating the Timeline for a BLA Filing Submission to 1H 2026, & Reports 2024 Unaudited Financial Results...

DBV Technologies Secures Agreement with FDA on Safety Exposure Data Required for BLA for Viaskin® Peanut Patch in 4–7-year-olds, Accelerating the Timeline for a BLA Filing Submission to 1H 2026, & Reports 2024 Unaudited Financial Results...
GlobeNewswire last month
DBV Technologies to Participate in Upcoming AAAAI/WAO Joint Congress

DBV Technologies to Participate in Upcoming AAAAI/WAO Joint Congress
GlobeNewswire 2 months ago
Half-Year Report on the DBV Technologies Liquidity Contract with ODDO BHF

Half-Year Report on the DBV Technologies Liquidity Contract with ODDO BHF
GlobeNewswire 3 months ago
DBV Technologies Announces Positive 3-Year Results from EPITOPE Phase 3 Open-Label Extension Study

DBV Technologies Announces Positive 3-Year Results from EPITOPE Phase 3 Open-Label Extension Study
GlobeNewswire 3 months ago
DBV Aligns With FDA On Accelerated Approval For Viaskin Peanut Patch In Younger Kids

DBV Aligns With FDA On Accelerated Approval For Viaskin Peanut Patch In Younger Kids
Benzinga 4 months ago
DBV Confirms Alignment with U.S. FDA on Accelerated Approval Pathway for the Viaskin® Peanut Patch in Toddlers 1 – 3 Years-Old

DBV Confirms Alignment with U.S. FDA on Accelerated Approval Pathway for the Viaskin® Peanut Patch in Toddlers 1 – 3 Years-Old
GlobeNewswire 4 months ago
View More